DGX$185.17
$185.16
Chart
Performance
Key Stats
AI DGX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyQuest Diagnostics shows solid fundamental strength with consistent profitability and a manageable debt level. Technical indicators are mixed, suggesting a neutral short-term outlook, while thematic positioning in healthcare diagnostics is stable but not as dynamic as growth tech sectors.
Thematic
Quest Diagnostics operates in the essential healthcare diagnostics sector. While demand for these services is stable, it lacks the explosive growth potential seen in rapidly evolving technology or biotech segments. The aging population and increasing focus on preventative healthcare provide steady tailwinds.
Fundamental
Quest Diagnostics exhibits strong profitability and efficient operations, with a well-managed balance sheet. Revenue and earnings have shown moderate growth, supported by a consistent dividend payout.
Technical
The stock is trading below key short-term moving averages, indicating some recent weakness. However, it remains above its longer-term averages and the RSI suggests it is neither overbought nor oversold, pointing to a neutral short-term momentum.
| Factor | Score |
|---|---|
| Healthcare Demand | 80 |
| Technological Advancement in Diagnostics | 60 |
| Regulatory Landscape | 70 |
| Market Competition | 55 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 80 |
| Growth | 75 |
| Balance Sheet Health | 70 |
| Cash Flow | 85 |
| Dividend | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 65 |
| Volume Confirmation | 75 |
| Support & Resistance | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
The company has exceeded earnings per share (EPS) estimates in 10 out of the last 12 quarters, with an average surprise of 4.6%, indicating consistent operational execution.
Undervalued Relative to Industry
The Price-to-Earnings (P/E) TTM ratio of 20.59 is below the industry average of 25.5, suggesting the stock may be undervalued compared to its peers.
Bearish Points (7)
Increasing P/S Ratio
The Price-to-Sales (P/S) ratio has increased from 1.7 in 2021 to 2.1 in 2023, which, coupled with slowing revenue growth, might indicate an elevated valuation expectation.
Slowing Revenue Growth
While annual revenue for 2024 is projected to be $9.87 billion, it represents a slowdown from $10.79 billion in 2021, suggesting potential challenges in top-line expansion.
Calendar
July 2025
7
Ex-Dividend Date
July 2025
21
Next Dividend Date
October 2025
21
Next Earnings Date
H: $2.57
A: $2.51
L: $2.48
H: 2.77B
A: 2.74B
L: 2.71B
Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Seasonals
Price Target
187.04 USD
The 39 analysts offering 1 year price forecasts for DGX have a max estimate of 200.00 and a min estimate of 158.69.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Major direct competitor offering a wide range of clinical laboratory and diagnostic services, often vying for similar contracts and patient bases.
Weight: 95
A global provider of analytical testing and clinical diagnostic services, directly competing with DGX in various markets and specialized areas.
Weight: 90
Specializes in innovative cancer diagnostics, including molecular tests like Cologuard, representing a segment where DGX also has a strong focus and competition.
Weight: 85
Specializes in cancer genetic testing and pathology services, making it a direct diagnostic competitor in the oncology field.